drugset / Trial / NCT03406962
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
Timeline
- Start
- 2018-02-09
- Primary completion
- 2020-02-10
- Completion
- 2021-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSC835 | Cell therapy | — | — |